Somato™: A Breakthrough in Natural Sleep Support, Now Alkemist Assured™
"We are thrilled to receive the Alkemist Assured seal for Somato™," said
Alkemist Labs is a recognized leader in natural products industry testing, known for its commitment to accuracy and transparency. Their Alkemist Assured program verifies the identity and purity of raw materials and finished products, providing valuable peace of mind for consumers who demand the best.
"Nutraland USA's decision to bring their Somato™ product into the Alkemist Assured program demonstrates their commitment to quality," said
Somato™ contains naturally occurring phytomelatonin, as well as other beneficial entourage compounds like Lycopene and GABA, found in tomatoes, and offers a 100% plant-based alternative to synthetic melatonin found in the vast majority of sleep supplements today. As part of Alkemist Labs' comprehensive program, Somato™ has undergone extensive testing for ingredient authenticity, identity, purity, potency, and contaminants. The Alkemist Assured seal provides customers with independent verification of Somato's origin from tomato fruit, and ensures it meets the highest standards for quality and transparency.
For more information about Somato™ and its Alkemist Assured certification, please visit www.somato.cc and www.alkemist.com/alkemist-assured/.
About Nutraland USA:
Nutraland USA is a leading supplier of sustainable, plant-based nutritional ingredients for food, beverage, and supplement products. The company is focused on clean-label, responsibly and ethically sourced, innovative products that meet the highest quality standards and serve the evolving needs of health-conscious consumers.
Contact:
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/somato-a-breakthrough-in-natural-sleep-support-now-alkemist-assured-302335876.html
SOURCE Nutraland USA, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scania to showcase its broad marine offering at SMM 2026
- European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
- Cwallet Launches Integrated Social Ecosystem to Eliminate Web3's Cross-Platform Security Gap
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share